Trial
NCT03926624
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Delta-Fly Pharma, Inc.
Collaborators
—
Condition
Leukemia, Myeloid, Acute
Intervention
DFP-10917
Why stopped
The data met the protocol-specified criteria for futility of the investigational treatment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-22